Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Moreau

Showing results (541-550 of 570) with videos related to

Pageof 57
Sort By:
Thrombosis and Haemostasis|December 8, 1998
French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune toleranceC Rothschild, Y Laurian, E P Satre, et al.
Plos One|March 19, 2015
Novel genetic locus implicated for HIV-1 acquisition with putative regulatory links to HIV replication and infectivity: a genome-wide association studyEric O Johnson, Dana B Hancock, Nathan C Gaddis, et al.
Leukemia|August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyP Moreau, D Joshua, W-J Chng, et al.
Leukemia|December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORW-J Chng, H Goldschmidt, M A Dimopoulos, et al.
ESMO Open|May 9, 2022
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 studyC Baldini, E Charton, E Schultz, et al.
Leukemia|April 6, 2013
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaX Leleu, G Fouquet, B Hebraud, et al.
ESMO Open|August 3, 2023
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 studyE Charton, C Baldini, Y Fayet, et al.
Bone Marrow Transplantation|May 29, 1998
Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registryP Moreau, J Fleury, P Brice, et al.
Human Immunology|January 4, 2001
HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expressionP Paul, N Rouas-Freiss, P Moreau, et al.
Leukemia|July 30, 2011
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyS K Kumar, J H Lee, J J Lahuerta, et al.
Pageof 57

Showing results (541-550 of 570) with videos related to

Sort By:
Pageof 57
Thrombosis and Haemostasis|December 8, 1998
French previously untreated patients with severe hemophilia A after exposure to recombinant factor VIII : incidence of inhibitor and evaluation of immune toleranceC Rothschild, Y Laurian, E P Satre, et al.
Plos One|March 19, 2015
Novel genetic locus implicated for HIV-1 acquisition with putative regulatory links to HIV replication and infectivity: a genome-wide association studyEric O Johnson, Dana B Hancock, Nathan C Gaddis, et al.
Leukemia|August 6, 2016
Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR studyP Moreau, D Joshua, W-J Chng, et al.
Leukemia|December 28, 2016
Carfilzomib-dexamethasone vs bortezomib-dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVORW-J Chng, H Goldschmidt, M A Dimopoulos, et al.
ESMO Open|May 9, 2022
Access to early-phase clinical trials in older patients with cancer in France: the EGALICAN-2 studyC Baldini, E Charton, E Schultz, et al.
Leukemia|April 6, 2013
Consolidation with VTd significantly improves the complete remission rate and time to progression following VTd induction and single autologous stem cell transplantation in multiple myelomaX Leleu, G Fouquet, B Hebraud, et al.
ESMO Open|August 3, 2023
Inequality factors in access to early-phase clinical trials in oncology in France: results of the EGALICAN-2 studyE Charton, C Baldini, Y Fayet, et al.
Bone Marrow Transplantation|May 29, 1998
Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin's disease: retrospective analysis of 158 cases from the French registryP Moreau, J Fleury, P Brice, et al.
Human Immunology|January 4, 2001
HLA-G, -E, -F preworkshop: tools and protocols for analysis of non-classical class I genes transcription and protein expressionP Paul, N Rouas-Freiss, P Moreau, et al.
Leukemia|July 30, 2011
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group studyS K Kumar, J H Lee, J J Lahuerta, et al.
Pageof 57